In Memory of William G. Harris at Soleno Therapeutics
It is with deep sadness that the team at Soleno Therapeutics, Inc. (NASDAQ: SLNO), a leading biopharmaceutical company focused on innovative therapies for rare diseases, shares the news of the passing of board member William G. "Bill" Harris. His journey with Soleno began in June 2014, and during that time, he became a treasured member of the Board of Directors.
A Tribute to a Trusted Leader
Dr. Anish Bhatnagar, the CEO and Chairman of the Board, reflected on his long-standing relationship with Bill, noting his integrity, practicality, and the heartfelt commitment he demonstrated towards helping others. Bill's profound insights and extensive experience as a senior executive in biopharmaceutical finance greatly benefited Soleno, especially during challenging times. The Board of Directors, alongside the entire Soleno family, sends heartfelt condolences to Bill’s loved ones during this difficult time.
William G. Harris’s Impressive Career
Mr. Harris's career in the biopharmaceutical sector commenced in the early 1990s at Gilead Sciences, where he quickly rose to the role of Director of Finance. He then transitioned to Coulter Pharmaceutical, a company dedicated to developing cutting-edge cancer therapies, where he served as Senior Vice President and Chief Financial Officer before its acquisition by Corixa Corp. in 2000. Following that, he took on leadership roles at Xenoport, Inc., further solidifying his reputation as a competent financial leader until the company was acquired by Arbor Pharmaceuticals in 2016.
Transitioning Leadership at Soleno
In light of Mr. Harris's passing, Andrew Sinclair, a long-serving member of the Board and Audit Committee, is poised to take on the role of Chair of the Audit Committee. Dr. Sinclair's qualifications as an "audit committee financial expert" align with the standards set by the Securities and Exchange Commission and are essential for Soleno's governance.
Soleno’s Commitment to Rare Diseases
Soleno Therapeutics is at the forefront of developing and commercializing innovative treatments targeting rare diseases. Its flagship product, VYKAT™ XR (diazoxide choline) extended-release tablets, offers a daily oral treatment option for hyperphagia in both children and adults diagnosed with Prader-Willi syndrome. The FDA's approval of this treatment marks a significant milestone in Soleno's mission to improve the lives of those living with rare conditions.
Future Endeavors and Commitment to Patients
Moving forward, Soleno is dedicated to turning its challenges into opportunities, aiming to broaden its portfolio and enhance the lives of patients relying on its therapeutics. The company's commitment remains steadfast as it pursues new avenues for innovation and development in the biopharmaceutical landscape.
Frequently Asked Questions
What happened to William G. Harris?
William G. Harris, a board member of Soleno Therapeutics, has passed away, leaving behind a significant legacy in the company.
What contributions did William G. Harris make to Soleno?
He provided valuable insights and guidance, significantly impacting Soleno’s strategic direction and growth during his tenure.
Who will take over after William G. Harris?
Andrew Sinclair is set to become the Chair of the Audit Committee following Mr. Harris's passing.
What is Soleno Therapeutics known for?
Soleno specializes in developing therapeutics for rare diseases, notably its product VYKAT™, approved for treating Prader-Willi syndrome.
How can I learn more about Soleno’s products?
For detailed information about their products and developments, you can visit Soleno Therapeutics’ official website.
